


PCR2020 e-Course

Flash report



e-Ultimaster

The biggest real world BP-DES registry crossing 4 continents⁽¹⁻²⁾



e-Ultimaster registry

37,198 patients enrolled

Clinical follow-up

0d

3m

1y

An independent Clinical Events Committee reviewed and adjudicated all endpoint-related serious adverse events

Dual antiplatelet therapy(DAPT) was at the discretion of the operator

Primary endpoint

Target lesion failure at 1 year

Cardiac death, target vessel MI or clinically driven target lesion revascularization

Secondary endpoint

Safety

Cardiac death/myocardial infarction
Stent thrombosis (according to ARC definitions; acute, subacute and late) Major vascular and bleeding complications

Efficacy and patient-oriented endpoints

Target lesion revascularization (TLR)
Target vessel failure (TVF) (Cardiac death, target vessel MI or clinically driven target vessel revascularization)
Patient-oriented composite endpoint (POCE)
(All-cause death, any MI or any coronary revascularization)

Study devices

UltimasterTM Sirolimus Eluting Coronary Stent System

Platform Thin strut, CoCr Open cell design

Polymer PDLLA PCL copolymer resorbed within 3-4 months

Coating Abluminal Gradient coating

Drug Sirolimus


[Learn more about Ultimaster BP-DES](#)



Total population

*"Ultimaster DES showed an excellent performance
at 1 year with a TLF rate <5% in all continents
and stent thrombosis rate <1% ⁽¹⁾"*

Marco Roffi



Total patients: 37,198


Europe: 25,736 (69%)

Asia: 6,614 (18%)

Africa/Middle East: 2,438 (7%)

S America/Mexico: 2,410 (6%)

Clinical outcomes at 1 year



**Are you interested in
geographical difference?**

Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



**e-ULTIMASTER registry: final
results and differences across
continents**

Bifurcation lesion

"4,395 patients with bifurcation lesions treated with Ultimaster DES showed excellent clinical outcomes with TLF 5.1% at 1 year ⁽²⁾"

Bernard Chevalier



Study protocol

Patient treated in Bifurcation lesion
n=4,395

True bifurcation

vs

Other bifurcation

POT

vs

No POT

Final kissing

vs


No Final kissing

One stent

vs

Two One stent

POT vs No POT on Ultimaster



Are you interested in other Bifurcation techniques ?

Check more information on PCR online

True bifurcation vs other bifurcation

Final kissing vs No Final kissing

One stent vs Two stent

Log in -> Sessions -> Hotline and Innovation ->



Bifurcation stenting: role of deployment technique in a global registry

Multivessel disease


"Ultimaster DES demonstrated excellent results even in this complex population" ⁽³⁾

David Hildick-Smith



Clinical outcomes at 12 months

Propensity score adjusted



Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



**Complete revascularisation
with the Ultimaster stent**


Complex PCI subgroups

"Overall ischemic event rates at 1 year in patients undergoing complex PCI were generally low"⁽⁴⁾


Mamas MAMAS



Study protocol



Clinical event rate at 1 year



Check more information on PCR online

Log in -> Sessions -> Hotline and Innovation ->



One-year clinical outcomes of complex PCI treated with use of Ultimaster stent

Contact

EMEA

Asia pacific

Latin America